• Eclipsebio integrated its unique portfolio of assays and computational algorithms to develop the eMERGE™ platform for the comprehensive characterization and precision optimization of RNA-based therapeutic products 
• Eclipsebio’s partners can improve the development of effective RNA medicines, vaccines, and gene therapies by accessing key data from the eMERGE platform, including measurements of translation efficiency, RNA structure, and miRNA regulation 

SAN DIEGO, July 24, 2024 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGE™ platform. eMERGE is an end-to-end solution for the characterization and optimization of RNA-based therapeutic products, including vaccines, protein and gene therapies, and monoclonal antibodies. The eMERGE platform will be available through integrative, full-service partnerships to support the development of more effective and safer RNA-based medicines.  

“The new eMERGE platform provides comprehensive solutions for biopharma partners facing a growing number of challenges characterizing mRNA, circular RNA, and self-amplifying RNA therapies,” said Eclipsebio CEO & co-founder Peter Chu, Ph.D. “eMERGE leverages our years of experience supporting our partners in developing cutting-edge RNA-based and RNA-targeting therapies, providing a true end-to-end solution for drug developers looking to characterize and improve all types of RNA-based medicines such as vaccines, protein replacement therapies, and more.”  

“With the increased emphasis on AI-enabled drug discovery, the eMERGE platform will also provide unique, high-quality data not available in public databases to accelerate the development of novel RNA design algorithms,” continued Dr. Chu. 

eMERGE enables Eclipsebio’s  partners to obtain actionable insights into RNA-based drug products through highly tailored collaborations. The all-inclusive platform includes detailed measurements of therapeutic translation, stability-influencing structure, RNA substance identity and integrity, and evaluations of LNP and storage effects. In addition to providing comprehensive characterization, the platform analyses provide guidance for precise optimizations to improve therapeutic efficacy including identification of optimal sequences for translation and stability.   

Eclipsebio will unveil eMERGE at Hanson Wade’s 4^th Annual mRNA-Based Therapeutics Summit on July 30, 2024. 

About Eclipsebio 

Eclipsebio is a private biotechnology company headquartered in San Diego developing first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With the company’s extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, they provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships, including custom assay development, for biopharma and as a la carte services for academics. For more information about Eclipsebio, visit www.eclipsebio.com.  

Contacts 

Media inquiries can be made to press@eclipsebio.com